期刊文献+

Pretreatment elevated fibrinogen level predicts worse oncologic outcomes in upper tract urothelial carcinoma

原文传递
导出
摘要 This study aimed to further validate the prognostic role of fibrinogen in upper tract urothelial carcinoma(UTUC)in a large Chinese cohort.A total of 703 patients who underwent radical nephroureterectomy were retrospectively identified.Fibrinogen levels of≥4.025 g l?1 were defined as elevated.Logistic regression analysis was performed to determine the association between fibrinogen and adverse pathological features.Kaplan–Meier analysis and Cox regression models were used to assess the associations of fibrinogen with cancer-specific survival(CSS),disease recurrence-free survival(RFS),and overall survival(OS).Harrell c-index and decision curve analysis were used to assess the clinical utility of multivariate models.The median follow-up duration was 42(range:1–168)months.Logistic regression analysis revealed that elevated fibrinogen was associated with higher tumor stage and grade,lymph node involvement,lymphovascular invasion,sessile carcinoma,concomitant variant histology,and positive surgical margins(all P<0.05).Multivariate Cox regression analysis demonstrated that elevated fibrinogen was independently associated with decreased CSS(hazard ratio[HR]:2.33;P<0.001),RFS(HR:2.09;P<0.001),and OS(HR:2.09;P<0.001).The predictive accuracies of the multivariate models were improved by 3.2%,2.0%,and 2.8%for CSS,RFS,and OS,respectively,when fibrinogen was added.Decision curve analysis showed an added benefit for CSS prediction when fibrinogen was added to the model.Preoperative fibrinogen may be a strong independent predictor of worse oncologic outcomes in UTUC;therefore,it may be valuable to apply this marker to the current risk stratification in UTUC.
出处 《Asian Journal of Andrology》 SCIE CAS CSCD 2020年第2期177-183,共7页 亚洲男性学杂志(英文版)
基金 This program was supported by the National key Research and Development program of China(Grant No.SQ2017YFSF090096) the Prostate Cancer Foundation Young Investigator Award 2013,the National Natural Science Foundation of China(Grant No.81300627,No.81370855,No.81702536,and No.81770756) Programs from Science and Technology Department of Sichuan Province(Grant No.2018JY0089 and No.2017HH0063) Young Investigator Award of Sichuan University 2017(Grant No.2017SCU04A17).The funders had no role in patient selection,data extraction,statistical analysis or interpretation,writing of this article,or the decision to publish.
  • 相关文献

参考文献1

二级参考文献31

  • 1Hundal R, Shaffer EA. Gallbladder cancer: epidemiology andoutcome. Clin Epidemiol 2014; 6: 99-109 [PMID: 24634588 DOI:10.2147/clep.s37357].
  • 2Wu XS, Shi LB, Li ML, Ding Q, Weng H, Wu WG, Cao Y, BaoRF, Shu YJ, Ding QC, Mu JS, Gu J, Dong P, Liu YB. Evaluationof two inflammation-based prognostic scores in patients withresectable gallbladder carcinoma. Ann Surg Oncol 2014; 21:449-457 [PMID: 24081806 DOI: 10.1245/s10434-013-3292-z].
  • 3Shu YJ, Weng H, Bao RF, Wu XS, Ding Q, Cao Y, Wang XA,Zhang F, Xiang SS, Li HF, Li ML, Mu JS, Wu WG, Liu YB.Clinical and prognostic significance of preoperative plasmahyperfibrinogenemia in gallbladder cancer patients followingsurgical resection: a retrospective and in vitro study. BMC Cancer2014; 14: 566 [PMID: 25096189 DOI: 10.1186/1471-2407-14-566].
  • 4Li M, Zhang Z, Li X, Ye J, Wu X, Tan Z, Liu C, Shen B, WangXA, Wu W, Zhou D, Zhang D, Wang T, Liu B, Qu K, Ding Q,Weng H, Ding Q, Mu J, Shu Y, Bao R, Cao Y, Chen P, Liu T, JiangL, Hu Y, Dong P, Gu J, Lu W, Shi W, Lu J, Gong W, Tang Z, ZhangY, Wang X, Chin YE, Weng X, Zhang H, Tang W, Zheng Y, He L,Wang H, Liu Y, Liu Y. Whole-exome and targeted gene sequencingof gallbladder carcinoma identifies recurrent mutations in the ErbBpathway. Nat Genet 2014; 46: 872-876 [PMID: 24997986 DOI:10.1038/ng.3030].
  • 5Choi SB, Han HJ, Kim CY, Kim WB, Song TJ, Suh SO, KimYC, Choi SY. Fourteen year surgical experience of gallbladdercancer: validity of curative resection affecting survival. Hepatogastroenterology2012; 59: 36-41 [PMID: 22251521 DOI:10.5754/hge10297].
  • 6Wang RT, Xu XS, Liu J, Liu C. Gallbladder carcinoma: analysisof prognostic factors in 132 cases. Asian Pac J Cancer Prev 2012;13: 2511-2514 [PMID: 22938413].
  • 7Feng JF, Huang Y, Lu WS, Chen QX. Preoperative platelet countin esophageal squamous cell carcinoma: is it a prognostic factor-Langenbecks Arch Surg 2013; 398: 1115-1122 [PMID: 24013712DOI: 10.1007/s00423-013-1111-4].
  • 8Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D,Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H. Preoperativeplatelet count associates with survival and distant metastasisin surgically resected colorectal cancer patients. J GastrointestCancer 2013; 44: 293-304 [PMID: 23549858 DOI: 10.1007/s12029-013-9491-9].
  • 9Brown KM, Domin C, Aranha GV, Yong S, Shoup M. Increasedpreoperative platelet count is associated with decreased survival afterresection for adenocarcinoma of the pancreas. Am J Surg 2005; 189:278-282 [PMID: 15792750 DOI: 10.1016/j.amjsurg.2004.11.014].
  • 10Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S,Pellegrinelli A, Labow D, Llovet JM, Schwartz M, Mazzaferro V.Resection of hepatocellular cancer .2 cm: results from two Westerncenters. Hepatology 2013; 57: 1426-1435 [PMID: 22576353 DOI:10.1002/hep.25832].

共引文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部